TriSalus Life Sciences Inc (TLSI)

Currency in USD
4.860
+0.310(+6.81%)
Closed·
4.950+0.090(+1.85%)
·
TLSI Scorecard
Full Analysis
Significant return over the last week
TLSI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.5524.948
52 wk Range
3.4205.989
Key Statistics
Prev. Close
4.86
Open
4.62
Day's Range
4.552-4.948
52 wk Range
3.42-5.989
Volume
112.15K
Average Volume (3m)
90.99K
1-Year Change
-15.48%
Book Value / Share
-0.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLSI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.313
Upside
+132.77%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

TriSalus Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

TriSalus Life Sciences Inc Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

TriSalus Life Sciences Inc Earnings Call Summary for Q2/2025

  • Q2 2025 net sales up 52% YoY to $11.2M; company reaffirms 50% revenue growth guidance for the year
  • Gross margin dipped to 84% from 88% in 2024; operating losses improved to $7.3M from $8.2M
  • Completed $22M private placement; cash position at $26.5M; targeting EBITDA positivity by early 2026
  • Expanding product portfolio and market position in liver embolization; exploring partnerships for nalotolimod
  • Stock near 52-week low of $3.42; InvestingPro analysis suggests undervaluation despite 37.5% decline over past year
Last Updated: 12/08/2025, 22:34
Read Full Transcript

Compare TLSI to Peers and Sector

Metrics to compare
TLSI
Peers
Sector
Relationship
P/E Ratio
−7.1x−1.9x−0.6x
PEG Ratio
−0.12−0.080.00
Price/Book
−12.5x2.4x2.6x
Price / LTM Sales
6.7x8.9x3.3x
Upside (Analyst Target)
126.3%75.8%39.1%
Fair Value Upside
Unlock4.2%4.5%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.313
(+132.77% Upside)

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.27 / --
Revenue / Forecast
11.21M / 11.59M
EPS Revisions
Last 90 days

TLSI Income Statement

People Also Watch

5.33
REPL
-4.14%
2.1100
DARE
-4.09%
1.350
COCH
-4.93%
1.240
VANI
-0.80%
0.344
VYNE
-2.00%

FAQ

What Stock Exchange Does TriSalus Life Sciences Trade On?

TriSalus Life Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for TriSalus Life Sciences?

The stock symbol for TriSalus Life Sciences is "TLSI."

What Is the TriSalus Life Sciences Market Cap?

As of today, TriSalus Life Sciences market cap is 240.36M.

What Is TriSalus Life Sciences's Earnings Per Share (TTM)?

The TriSalus Life Sciences EPS (TTM) is -1.18.

From a Technical Analysis Perspective, Is TLSI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has TriSalus Life Sciences Stock Split?

TriSalus Life Sciences has split 0 times.

How Many Employees Does TriSalus Life Sciences Have?

TriSalus Life Sciences has 110 employees.

What is the current trading status of TriSalus Life Sciences (TLSI)?

As of 19 Aug 2025, TriSalus Life Sciences (TLSI) is trading at a price of 4.86, with a previous close of 4.86. The stock has fluctuated within a day range of 4.55 to 4.95, while its 52-week range spans from 3.42 to 5.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.